Qiming Weekly | Top 10 Updates from Qiming Venture Partners Portfolio Companies Vol.29, 2026.9.9
Celebrating milestone moments with you at Qiming Venture Partners portfolio companies
Editor's Note: In 2026, the Qiming Weekly has been upgraded and refreshed, with regular weekly updates featuring only ten major developments from Qiming Venture Partners portfolio companies, covering funding progress and breakthroughs.
Every step entrepreneurs take in the tide of technology and innovation deserves to be recorded. Qiming Venture Partners will continue to accelerate and empower entrepreneurs, and join you in tracking milestone moments for our portfolio companies.
Major Partnerships
01/ Insilico Medicine and MobiDrop Enter Strategic Partnership
Recently, Qiming Venture Partners portfolio company Insilico Medicine (03696.HK), a generative AI-driven clinical-stage biotech firm, announced a strategic partnership with MobiDrop, a single-cell and multi-omics technology company focused on scalable, high-quality AI-ready life science data. The two parties will collaborate deeply on the production, integration, and application of high-quality, traceable, AI-ready single-cell data. MobiDrop's large-scale multi-omics output will be systematically fed into Insilico Medicine's Pharma.AI platform data repository, providing training, validation, and model iteration support for its core generative biology platform PandaOmics and its newly released multi-agent-driven Virtual Aging Cell platform (VAC).
Per the agreement, the two sides will establish a long-term, non-exclusive strategic cooperation mechanism covering target validation, disease mechanism research, biomarker discovery, and indication selection. Insilico Medicine will select real R&D needs from its internal pipeline as application scenarios; MobiDrop will leverage its proprietary single-cell technology, automated experimental platform, and intelligent analysis system to deliver high-quality experimental data meeting AI-ready standards at scale. Generated project data will be fed back to the Insilico Medicine platform for model evaluation, forming a continuous iteration loop of "data production, model iteration, R&D acceleration, and new data demand."
02/ Infinigence AI and Jiyuan Lüdong Jointly Release First Agent-Native Model NeoHorse-1
Recently, Qiming Venture Partners portfolio company Infinigence AI and Jiyuan Lüdong jointly released NeoHorse-1, the first Agent-Native model, exploring a Harness-driven RSI path. Both parties collaborated with Tsinghua University and Peking University teams on algorithm and training methodology research, jointly exploring new approaches to improve post-training data utilization efficiency and training effectiveness for Agents.
NeoHorse-1 comes in 4B and 9B versions, systematically converting Agent experience in tool use, feedback reception, and error correction into intrinsic model capabilities. Across ten benchmarks covering Harness Agent, tool use, coding, and instruction following, the 4B model after Agentic Post-Training achieved comprehensive performance reaching or slightly exceeding that of the 9B base model.
03/ Noitom Robotics and Deep Wit Reach Strategic Partnership
Recently, Qiming Venture Partners portfolio company Noitom Robotics formally signed a strategic cooperation agreement with Deep Wit, establishing a strategic partnership. The two parties will collaborate on high-quality human data and embodied foundation model training, combining Noitom Robotics' technical accumulation in real-world data collection including motion capture and human-object interaction with Deep Wit's capabilities in physical intelligence and embodied foundation models, jointly exploring the technical path from data to robot capability verification.
As the first concrete outcome of this partnership, Deep Wit will incorporate high-quality data provided by Noitom Robotics for embodied model training and related technical validation. Going forward, both parties will also conduct further exploration around data theme design, data structuring, training effectiveness evaluation, and robot capability verification based on actual needs arising from model training.
04/ XSKY Reaches Strategic Partnership with GPUStack
Recently, the GPUStack AI Infra Ecosystem and Technology Innovation Conference was held in Beijing. At the conference, Qiming Venture Partners portfolio company XSKY formally signed a strategic cooperation agreement with GPUStack. Both parties will leverage their respective strengths in AI data infrastructure and model deployment management, collaborating on shared KV Cache, inference acceleration, and heterogeneous compute adaptation to jointly build AI infrastructure for Token factories.
The essence of this cooperation is deep synergy between the storage layer and compute scheduling layer. The combination of XSKY MeshFusion's shared cache capabilities and GPUStack's model deployment management capabilities enables KV Cache to truly move from underlying technical capability to model deployment and operations workflows. As AI applications evolve from single-turn Q&A to complex workflows, this integrated "storage + compute" architecture provides enterprises with a viable path for AI implementation that balances efficiency and cost.
Product Launches
01/ Axera Officially Launches M9 Series
Recently, Qiming Venture Partners portfolio company Axera officially launched its M9 series of high-end intelligent driving chips. The flagship M97 and mainstream M95 are two 5nm advanced-process automotive-grade chips with AI compute power up to 720 TOPS, built on a unified architecture that systematically resolves the underlying bottlenecks for large-model intelligent driving deployment across compute, frame rate, latency, image quality, and memory bandwidth.
As of August 2026, Axera's cumulative global shipments of intelligent driving chips have exceeded 1.6 million units, with the M5 series already achieving large-scale mass production deployment. Building on this established industrial scale, the launch of the M9 series high-end intelligent driving chips carries a core strategic mission: to build an autonomous and controllable domestic intelligent driving compute foundation, adhering to "open ecosystem, no competition with partners," and fully unleashing the algorithmic autonomy of automakers and Tier 1 suppliers. The M9 series launch also marks Axera's strategic upgrade from scaled mass production in assisted driving to breakthrough in the high-end intelligent driving market.
02/ DeepWise Launches Solid-State Electrolyte Intelligent R&D Large-Scale Facility Product
Recently, at the 2026 World Power Battery Conference held in Yibin, Sichuan, Qiming Venture Partners portfolio company DeepWise formally unveiled its solid-state electrolyte intelligent R&D large-scale facility product to the global audience.
This public product launch signifies that this R&D infrastructure has officially moved from proof-of-concept to industrial-scale application. The large-scale facility打通 the complete technical chain of read-compute-do, with MatMaster playing the role of "AI scientist" for assisted decision-making; using the DPA-4 large atomic scientific model as the computational foundation, it derives the solid-state electrolyte vertical DPA-SSE model, relying on the Uni-Lab-OS intelligent laboratory system, combined with critical process modifications including mixing and sintering and full-process automation, to achieve deep integration of computation and physical experimentation, building a closed-loop iterative optimization self-developed system.
Technology & Capabilities
01/ Sharpa and DQ Launch World's First "Zero Retrofit, Fully Autonomous, Year-Round" Robot Restaurant
Recently, the world's first "zero retrofit, fully autonomous, year-round" robot Blizzard restaurant opened at DQ's Shanghai Wujiang Road location. This restaurant, jointly created by Qiming Venture Partners portfolio company Sharpa and Dairy Queen (hereinafter "DQ"), a globally renowned ice cream and fast-food chain operated by CFB Group, marks Sharpa's first industry achievement of completing complex production tasks in a real commercial scenario: fully autonomously executing the 55-step complex continuous process from order to production to delivery of a Blizzard ice cream, operating stably during daily business hours from 10:00 to 22:00, year-round, without continuous human control.
This collaboration marks Sharpa's overcoming of three major challenges in commercial robot deployment: heavy reliance on customized equipment for deployment, insufficient AI capabilities to support complex long-horizon tasks, and inadequate reliability to stably create commercial value. The robot restaurant jointly created by Sharpa and DQ formally advances the evaluation standard for robot commercialization from "completing tasks" to a new stage of "delivering complete productivity."
01/
CIX Technology Showcases Agentic Compute Full-Scenario Solutions at 2026 Consumer Electronics Expo
Recently, the 2026 China International Consumer Electronics Expo (hereinafter "CE Expo") was held in Qingdao. Qiming Venture Partners portfolio company CIX Technology showcased core products including the AGX Station and digital employee intelligent agent solutions at the AI Large Models and Intelligent Computing Terminals pavilion, comprehensively demonstrating full-scenario Agentic Compute capabilities from underlying chips to terminal applications.
At the AI Large Models and Intelligent Computing Terminals pavilion, CIX Technology, as a representative enterprise in chips and AI computing, showcased its latest technological achievements in the Agentic Compute domain at the Laoshan District software and electronic information industry exhibition area. During the expo, the Laoshan District software and electronic information industry themed promotion event and industrial chain supply-demand matchmaking conference was held on-site. Fu Yanhao, CIX Technology's regional senior manager, shared the company's technical roadmap and implementation practices in the Agentic Compute domain. He stated that with self-developed chips, system solutions, and AI intelligence as foundations, CIX Technology focuses on the intelligent agent CPU core domain and has completed the full-chain layout from technological innovation to scenario implementation.
02/
MediLink Therapeutics' Tam-Peli for Relapsed Small Cell Lung Cancer NDA Accepted by CDE
Qiming Venture Partners portfolio company MediLink Therapeutics announced that the Center for Drug Evaluation, NMPA (hereinafter "CDE") has accepted the company's New Drug Application for its self-developed B7-H3-targeting antibody-drug conjugate injection Tam-Peli (YL201) for the treatment of relapsed small cell lung cancer, with acceptance number CXSS2600135. Tam-Peli has also been granted priority review status. This application is based on results from a Phase III clinical trial in relapsed small cell lung cancer (trial number: TAISHAN-302), which has met its primary OS endpoint. Complete efficacy and safety data will be presented as an oral report at the 2026 World Conference on Lung Cancer (WCLC) Presidential Symposium.
This marks the second indication for which Tam-Peli's NDA has been accepted by the CDE, and also makes it the world's first ADC drug to receive NDA acceptance for small cell lung cancer based on Phase III clinical data. On July 17, 2026, the CDE accepted the NDA for Tam-Peli for third-line and beyond treatment of nasopharyngeal carcinoma.
03/
Belief BioMed Completes First Patient Dosing in Registration Clinical Study of Gene Therapy for Cervical HSIL
Qiming Venture Partners portfolio company Belief BioMed, an innovative enterprise focused on cutting-edge gene therapy, announced that the registration Phase I clinical study (CTR20262330) of its self-developed gene therapy drug BBM-C101 injection for cervical high-grade squamous intraepithelial lesion (HSIL), conducted under the leadership of Professor Wang Jianliu and Director Fang Yi at Peking University People's Hospital, has successfully completed first patient dosing.
This clinical trial is an open-label, multiple-dose study designed to evaluate the safety, tolerability, immunogenicity, and preliminary efficacy of subcutaneous BBM-C101 injection in female patients aged 18-55 with confirmed HPV16 and/or HPV18 infection-related HSIL. BBM-C101 uses a non-replicating recombinant adenovirus (rAd) as a vector, which can co-express HPV antigens and immune activation factors in host cells, potentially offering a gene therapy option for patients with HPV16 and/or HPV18-related HSIL.
PAST REVIEWS
Qiming Perspectives | Duane Kuang, Qiming Venture Partners: Embrace the Cycle, Ride Through the Cycle — AI Will Be an Ultra-Long Technology Cycle Qiming Weekly | Ten Major Developments from Qiming Venture Partners Portfolio Companies Vol. 26, 2026.8.18 Qiming Headlines | Qiming Venture Partners and Portfolio Companies Win Multiple Awards Including No. 4 on ChinaVenture's 2025 Best VC Firms List
Qiming Venture Partners was founded in 2006. Currently, the firm manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since its inception, Qiming Venture Partners has focused on investing in outstanding early and growth-stage companies in Technology and Healthcare.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have gone public on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. Over 80 portfolio companies have become recognized unicorns or super-unicorns.
Many Qiming Venture Partners portfolio companies have grown into the most influential companies in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ: BILI, 09626.HK), Zhihu (NYSE: ZH, 02390.HK), Roborock (688169.SH), Hesai Technology (NASDAQ: HSAI, 02525.HK), UBTECH (09880.HK), WeRide (NASDAQ: WRD, 00800.HK), HyperStrong (688411.SH), Insta360 (688775.SH), Unisound (09678.HK), Biren Technology (06082.HK), Zhipu AI (02513.HK), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ: ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ: SDGR), APT Medical (688617.SH), Sanyou Medical (688085.SH), AmoyDx (300685.SZ), Sinocelltech (688520.SH), Insilico Medicine (03696.HK), AusperBio, Yuanxin Technology, MediLink Therapeutics, Leads Biolabs, StepFun, and others.